FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PARKINSON ROBERT L JR				ENZ	2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC [enzn]								Check all ap	plicable) ctor	.,	Person(s) to Issuer		
(Last)	(Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/31/2003								Offi belo	cer (give title ow)		Other (specify below)	
685 ROUTE 202/206				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BRIDGEWATER NJ 08807 (City) (State) (7ip)													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Oily)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day				tion	2A. Exe	A. Deemed recution Date,		3. Transa	3. 4. Transaction Di Code (Instr. an		ecurities Acquired (posed Of (D) (Instr. 5)		3) or 5. An 4 Secu Bene Owne	nount of rities ficially	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership		
								Code	\	V Amou	nt (A) or Prid				(Instr. 4)	(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transact Code (In 8)		Number		6. Date Exercisal Expiration Date (Month/Day/Year		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amoun or Numbe of Shares					
Common Stock Right ⁽¹⁾	(2)	12/31/2003			A		293		(1)		(1)	Common Stock	293	\$0	293	D		
Common Stock (right to buy) ⁽³⁾	\$12.15	01/02/2004			A		5,000		01/01/200	5	01/01/2014	Common Stock	5,000	\$0	5,000	D		

Explanation of Responses:

- 1. Securities granted by Enzon Pharmaceuticals, Inc. pursuant to Enzon's 2001 Incentive Stock Plan as compensation for service as an Independent Director during the quarter ended December 31, 2003 and qualified under Rule 16b-3(d). The value of the compensation was \$3,500. In the spring of 2004, each Common Stock Right will be exchanged for one share of Common Stock; provided, however, Mr. Parkinson will be entitled to elect to receive cash for up to 50% of these rights, with the price per right being \$11.97, the fair market value of Enzon's Common Stock on December 31, 2003.
- 2. Each Common Stock Right that is exchanged will be exchanged for one share of Enzon's Common Stock.
- 3. Annual option granted to the Independent Directors of Enzon pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).

/s/ Kenneth J. Zuerblis (Attorney-in-fact) 01/05/2004

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.